Phase 2 Anatomic Stage IV Breast Cancer AJCC v8 trials recruiting now

All Anatomic Stage IV Breast Cancer AJCC v8 trials, every phase

Other phases for Anatomic Stage IV Breast Cancer AJCC v8

Phase 2 Anatomic Stage IV Breast Cancer AJCC v8 trials

• A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer
  NCT07078604 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
  NCT07112053 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.
  NCT04305834 · Phase: Phase 2 · Ages: 70 Years and older · Sex: All (male and female) · 6 locations
• Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer
  NCT06525766 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
  NCT04771520 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer
  NCT06860815 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
  NCT04348747 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 3 locations
• Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
  NCT06179303 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
  NCT06026657 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer
  NCT06492759 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
  NCT06518057 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer
  NCT05318469 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial
  NCT07158021 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
  NCT04090567 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
  NCT05269381 · Phase: Phase 1, Phase 2 · Ages: 16 Years and older · Sex: All (male and female) · 2 locations
• Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non-small Cell Lung Cancer
  NCT06910761 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer
  NCT05741164 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 2 locations
• Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer
  NCT06260033 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer
  NCT06434064 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
  NCT05564377 · Phase: Phase 2 · Ages: No age limits stated · Sex: All (male and female) · 482 locations
• Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
  NCT03606967 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 30 locations
• [18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer
  NCT06502691 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

What does Phase 2 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.